CML, driven by the BCR-ABL fusion gene, is typically treated with tyrosine kinase inhibitors (TKIs) like imatinib, but resistance remains a major challenge. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.